Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and small…
Dr Ali Jazayeri – Chief Scientific Officer Dr Giles Brown – VP, Medicinal Chemistry Dr Hsin Loke – VP, Head of…
– Developing novel medicines using structural mass spectrometry – Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biopharmaceutical company using…
Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding…